Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 18, 2017 - Issue 5
Submit an article Journal homepage
668
Views
64
CrossRef citations to date
0
Altmetric
Original Investigation

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial

Chun-Yuan LinGraduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan; ;Tsaotun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan; ;National Changhua University of Education, Changhua, Taiwan;
,
Sun-Yuan LiangDepartment of Psychiatry, Changhua Hospital, Ministry of Health and Welfare, Changhua, Taiwan;
,
Yue-Cune ChangDepartment of Mathematics, Tamkang University, Taipei, Taiwan;
,
Shuo-Yen TingDepartment of Psychiatry, Changhua Hospital, Ministry of Health and Welfare, Changhua, Taiwan;
,
Ching-Ling KaoTsaotun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan;
,
Yu-Hsin WuNational Changhua University of Education, Changhua, Taiwan; ;Feng-Yuan Hospital, Ministry of Health and Welfare, Taichung, Taiwan;
,
Guochuan E. TsaiDepartment of Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, USA;
&
Hsien-Yuan LaneGraduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan; ;Department of Psychiatry, China Medical University Hospital, Taichung, TaiwanCorrespondence[email protected]
 show all
Pages 357-368 | Received 03 Mar 2015, Accepted 04 Nov 2015, Published online: 22 Dec 2015

Citations (64)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mattia Marchi, Giacomo Galli, Federica Maria Magarini, Giorgio Mattei & Gian Maria Galeazzi. (2021) Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Expert Opinion on Drug Metabolism & Toxicology 17:4, pages 483-493.
Read now
Susan F. Sonnenschein & A Grace. (2021) Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis. Expert Opinion on Therapeutic Targets 25:1, pages 15-26.
Read now

Articles from other publishers (62)

Hsien-Yuan Lane, Shi-Heng Wang & Chieh-Hsin Lin. (2023) Adjunctive transcranial direct current stimulation (tDCS) plus sodium benzoate for the treatment of early-phase Alzheimer's disease: A randomized, double-blind, placebo-controlled trial. Psychiatry Research, pages 115461.
Crossref
Evangelia Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras & Konstantinos N. Fountoulakis. (2023) Novel Compounds in the Treatment of Schizophrenia—A Selective Review. Brain Sciences 13:8, pages 1193.
Crossref
Chuanjun Zhuo, Hongjun Tian, Xueqin Song, Deguo Jiang, Guangdong Chen, Ziyao Cai, Jing Ping, Langlang Cheng, Chunhua Zhou & Chunmian Chen. (2023) Microglia and cognitive impairment in schizophrenia: translating scientific progress into novel therapeutic interventions. Schizophrenia 9:1.
Crossref
Chih-Chia Huang, I-Hua Wei, Hui-Ting Yang & Hsien-Yuan Lane. (2023) Determination of D-serine and D-alanine Tissue Levels in the Prefrontal Cortex and Hippocampus of Rats After a Single Dose of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, with Potential Antipsychotic and Antidepressant Properties. Neurochemical Research 48:7, pages 2066-2076.
Crossref
Toral S. Surti, Mohini Ranganathan, Jason K. Johannesen, Ralitza Gueorguieva, Emma Deaso, Joshua G. Kenney, John H. Krystal & Deepak Cyril D'Souza. (2023) Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 256, pages 36-43.
Crossref
Chieh-Hsin Lin & Hsien-Yuan Lane. (2023) Sodium benzoate: A novel multi-target pharmaceutical approach to rescue clozapine-resistant schizophrenia. Schizophrenia Research.
Crossref
Ping Yin, Xi Han, Li Yu, Huifen Zhou, Jiehong Yang, Ying Chen, Ting Zhang & Haitong Wan. (2023) Pharmacokinetic analysis for simultaneous quantification of Saikosaponin A- paeoniflorin in normal and poststroke depression rats: A comparative study. Journal of Pharmaceutical and Biomedical Analysis, pages 115485.
Crossref
Asim A. Shah & Syed Z. Iqbal. (2023) Recent Advances in Psychopharmacology: From Bench to Bedside Novel Trends in Schizophrenia. Journal of Personalized Medicine 13:3, pages 411.
Crossref
Hsien‐Yuan Lane, Shi‐Heng Wang & Chieh‐Hsin Lin. (2022) Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease. Psychiatry and Clinical Neurosciences 77:2, pages 102-109.
Crossref
Andreas O. Kruse & Juan R. Bustillo. (2022) Glutamatergic dysfunction in Schizophrenia. Translational Psychiatry 12:1.
Crossref
Chien-Yi Kuo, Chieh-Hsin Lin & Hsien-Yuan Lane. (2022) Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research. CNS Drugs 36:11, pages 1143-1153.
Crossref
Chih-Hung Lin, Po-Chang Shih & Guochuan Emil Tsai. 2022. Ketamine Revisited - New Insights into NMDA Inhibitors. Ketamine Revisited - New Insights into NMDA Inhibitors.
Chieh-Hsin Lin, Shi-Heng Wang & Hsien-Yuan Lane. (2022) Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial. International Journal of Neuropsychopharmacology 25:7, pages 545-555.
Crossref
Tanja Veselinović & Irene Neuner. (2022) Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 36:8, pages 819-858.
Crossref
Andrea de Bartolomeis, Licia Vellucci, Mark C. Austin, Giuseppe De Simone & Annarita Barone. (2022) Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics. Biomolecules 12:7, pages 909.
Crossref
Łucja Justyna Walczak-Nowicka & Mariola Herbet. (2022) Sodium Benzoate—Harmfulness and Potential Use in Therapies for Disorders Related to the Nervous System: A Review. Nutrients 14:7, pages 1497.
Crossref
Jyothsna Chinnapura Seetharam, Rituparna Maiti, Archana Mishra & Biswa Ranjan Mishra. (2022) Efficacy and safety of add-on sodium benzoate, a D-amino acid oxidase inhibitor, in treatment of schizophrenia: A systematic review and meta-analysis. Asian Journal of Psychiatry 68, pages 102947.
Crossref
Julia Cappelli, Pamela Khacho, Boyang Wang, Alexandra Sokolovski, Wafae Bakkar, Sophie Raymond, Nina Ahlskog, Julian Pitney, Junzheng Wu, Prakash Chudalayandi, Adrian Y.C. Wong & Richard Bergeron. (2022) Glycine-induced NMDA receptor internalization provides neuroprotection and preserves vasculature following ischemic stroke. iScience 25:1, pages 103539.
Crossref
Carolina Muguruza & Luis F. Callado. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders 493 521 .
Andrea Baker, Lachlan Clarke, Peter Donovan, Jacobus P. J. Ungerer, Gunter Hartel, George Bruxner, Luca Cocchi, Anne Gordon, Vikas Moudgil, Gail Robinson, Digant Roy, Ravinder Sohal, Emma Whittle & James G. Scott. (2021) Cadence discovery: study protocol for a dose-finding and mechanism of action clinical trial of sodium benzoate in people with treatment-refractory schizophrenia. Trials 22:1.
Crossref
Yu-Jung Cheng, Chieh-Hsin Lin & Hsien-Yuan Lane. (2021) d-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia. International Journal of Molecular Sciences 22:20, pages 10917.
Crossref
Ju-Chun Pei, Da-Zhong Luo, Shiang-Shin Gau, Chia-Yuan Chang & Wen-Sung Lai. (2021) Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia. Frontiers in Psychiatry 12.
Crossref
Nicholas R Livingston, Peter CT Hawkins, James Gilleen, Rong Ye, Lorena Valdearenas, Sukhi S Shergill & Mitul A Mehta. (2021) Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. Journal of Psychopharmacology 35:9, pages 1099-1110.
Crossref
Darko Vušak, Neven Smrečki, Senada Muratović, Dijana Žilić, Biserka Prugovečki & Dubravka Matković-Čalogović. (2021) Structural diversity in the coordination compounds of cobalt, nickel and copper with N -alkylglycinates: crystallographic and ESR study in the solid state . RSC Advances 11:38, pages 23779-23790.
Crossref
Wenjia Wang, Yongjie Zhou, Ran Liu, Shuochi Wei, Hang Xu, Jiesi Wang, Li Wang, Tammy H. Trinh, Hanjing E. Wu, Dongmei Wang & Xiangyang Zhang. (2021) Association between empathy and clinical symptoms in chronic schizophrenia: A large sample study based on Chinese Han population. Journal of Psychiatric Research 139, pages 106-112.
Crossref
Chieh-Hsin Lin, Ping-Kun Chen, Shi-Heng Wang & Hsien-Yuan Lane. (2021) Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia. JAMA Network Open 4:4, pages e216156.
Crossref
Kazuyuki Fujihara, Takumi Sato, Kazuya Higeta, Yoshiki Miyasaka, Tomoji Mashimo & Yuchio Yanagawa. (2021) Behavioral Consequences of a Combination of Gad1 Haplodeficiency and Adolescent Exposure to an NMDA Receptor Antagonist in Long-Evans Rats. Frontiers in Pharmacology 12.
Crossref
Kah Kheng Goh, Tzu-Hua Wu, Chun-Hsin Chen & Mong-Liang Lu. (2021) Efficacy of N -methyl- D -aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials . Journal of Psychopharmacology 35:3, pages 236-252.
Crossref
W Wolfgang Fleischhacker, Jana Podhorna, Martina Gröschl, Sanjay Hake, Yihua Zhao, Songqiao Huang, Richard S E Keefe, Michael Desch, Ronald Brenner, David P Walling, Emilio Mantero-Atienza, Kazuyuki Nakagome & Stephane Pollentier. (2021) Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The Lancet Psychiatry 8:3, pages 191-201.
Crossref
James G. Scott, Andrea Baker, Carmen C. W. Lim, Sharon Foley, Frances Dark, Anne Gordon, David Ward, Drew Richardson, George Bruxner, K. Martin Beckmann, Sean Hatherill, Stephen Stathis, Krystal Dixon, Alexander E. Ryan, Brett C. McWhinney, Jacobus P. J. Ungerer, Michael Berk, Olivia M. Dean, Sukanta Saha & John McGrath. (2020) Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis. JAMA Network Open 3:11, pages e2024335.
Crossref
Bruno Lemes Marques, Onésia Cristina Oliveira-Lima, Gustavo Almeida Carvalho, Raphaela de Almeida Chiarelli, Raul Izidoro Ribeiro, Ricardo Cambraia Parreira, Elis Marra da Madeira Freitas, Rodrigo Ribeiro Resende, Friederike Klempin, Henning Ulrich, Renato Santiago Gomez & Mauro Cunha Xavier Pinto. (2020) Neurobiology of glycine transporters: From molecules to behavior. Neuroscience & Biobehavioral Reviews 118, pages 97-110.
Crossref
Motohiro Okada, Yasuhiro Kawano, Kouji Fukuyama, Eishi Motomura & Takashi Shiroyama. (2020) Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions. International Journal of Molecular Sciences 21:21, pages 7951.
Crossref
José Andrés Espejo Oltra. (2020) Improving Therapeutic Interventions of Schizophrenia with Advances in Stem Cell Technology. Clinical Psychopharmacology and Neuroscience 18:3, pages 352-361.
Crossref
Gerson D. Guercio, Yuri Anjos-Travassos, Igor Rangel, Stella Costa, André Poleto, Deborah Costa, Rafaela Chaiben, Etienne de Villers-Sidani & Rogério Panizzutti. (2020) Auditory cognitive training improves prepulse inhibition in serine racemase mutant mice. Psychopharmacology 237:8, pages 2499-2508.
Crossref
Albert Adell. (2020) Brain NMDA Receptors in Schizophrenia and Depression. Biomolecules 10:6, pages 947.
Crossref
Chun-Hung Chang, Chieh-Hsin Lin, Chieh-Yu Liu, Shaw-Ji Chen & Hsien-Yuan Lane. (2020) Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology 34:5, pages 495-505.
Crossref
Kevin C.F. Fone, David J.G. Watson, Rodolphe I. Billiras, Dorothee I. Sicard, Anne Dekeyne, Jean-Michel Rivet, Alain Gobert & Mark J. Millan. (2020) Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management. Molecular Neurobiology 57:5, pages 2144-2166.
Crossref
Chieh-Hsin Lin, Yu-Ming Chen & Hsien-Yuan Lane. (2020) Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. Current Drug Targets 21:6, pages 610-615.
Crossref
Chun-Hung Chang, Chieh-Hsin Lin & Hsien-Yuan Lane. (2020) d-glutamate and Gut Microbiota in Alzheimer’s Disease. International Journal of Molecular Sciences 21:8, pages 2676.
Crossref
Yuli Huang, Haoxiao Zheng, Kuan Tan, Xiangdong Sun, Jinshao Ye & Yunlong Zhang. (2020) Circulating metabolomics profiling reveals novel pathways associated with cognitive decline in patients with hypertension. Therapeutic Advances in Neurological Disorders 13, pages 175628642094797.
Crossref
Ju-Chun Pei, Wei-Li Hung, Bei-Xuan Lin, Min-Han Shih, Liang-Yin Lu, Da-Zhong Luo, Hwan-Ching Tai, Vincent Studer, Ming-Yuan Min & Wen-Sung Lai. (2019) Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia. Journal of Psychopharmacology 33:10, pages 1288-1302.
Crossref
Scott Andrew Wegner, Bing Hu, Thatiane De Oliveira Sergio, David Darevsky, Claudina Choi-Yan Kwok, Kelly Lei & Frederic Woodward Hopf. (2019) A novel NMDA receptor-based intervention to suppress compulsion-like alcohol drinking. Neuropharmacology 157, pages 107681.
Crossref
Naista Zhand, David G. Attwood & Philip D. Harvey. (2019) Glutamate modulators for treatment of schizophrenia. Personalized Medicine in Psychiatry 15-16, pages 1-12.
Crossref
Bahareh Peyrovian, Joshua D. Rosenblat, Zihang Pan, Michelle Iacobucci, Elisa Brietzke & Roger S. McIntyre. (2019) The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 92, pages 387-404.
Crossref
G.D. Guercio, M.E. Thomas, J.M. Cisneros-Franco, P. Voss, R. Panizzutti & E. de Villers-Sidani. (2019) Improving cognitive training for schizophrenia using neuroplasticity enhancers: Lessons from decades of basic and clinical research. Schizophrenia Research 207, pages 80-92.
Crossref
Joshua T. Kantrowitz. (2019) N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia. Schizophrenia Research 207, pages 70-79.
Crossref
Chun-Hung Chang, Hsien-Yuan Lane, Ping-Tao Tseng, Shaw-Ji Chen, Chieh-Yu Liu & Chieh-Hsin Lin. (2019) Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology 33:4, pages 436-448.
Crossref
Jin-Bo Yu, Zhen-Xiong Zhao, Ran Peng, Li-Bin Pan, Jie Fu, Shu-Rong Ma, Pei Han, Lin Cong, Zheng-Wei Zhang, Li-Xin Sun, Jian-Dong Jiang & Yan Wang. (2019) Gut Microbiota-Based Pharmacokinetics and the Antidepressant Mechanism of Paeoniflorin. Frontiers in Pharmacology 10.
Crossref
Julia F. Hyslop, Sarah L. Lovelock, Allan J.B. Watson, Peter W. Sutton & Gheorghe-Doru Roiban. (2019) N-Alkyl-α-amino acids in Nature and their biocatalytic preparation. Journal of Biotechnology 293, pages 56-65.
Crossref
Cheng-Hao Tu, Iona MacDonald & Yi-Hung Chen. (2019) The Effects of Acupuncture on Glutamatergic Neurotransmission in Depression, Anxiety, Schizophrenia, and Alzheimer's Disease: A Review of the Literature. Frontiers in Psychiatry 10.
Crossref
Ragy R. Girgis, Anthony W. Zoghbi, Daniel C. Javitt & Jeffrey A. Lieberman. (2019) The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of Psychiatric Research 108, pages 57-83.
Crossref
Borja Santos, Eduardo González-Fraile, Arantzazu Zabala, Virginia Guillén, José R Rueda & Javier Ballesteros. (2018) Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. Journal of Psychopharmacology 32:11, pages 1155-1166.
Crossref
Deepnath Bajani, Debmalya Gharai & Joykrishna Dey. (2018) A comparison of the self-assembly behaviour of sodium N-lauroyl sarcosinate and sodium N-lauroyl glycinate surfactants in aqueous and aqueo-organic media. Journal of Colloid and Interface Science 529, pages 314-324.
Crossref
Igne Sinkeviciute, Marieke Begemann, Merel Prikken, Bob Oranje, Erik Johnsen, Wan U. Lei, Kenneth Hugdahl, Rune A. Kroken, Carina Rau, Jolien D. Jacobs, Silvia Mattaroccia & Iris E. Sommer. (2018) Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. npj Schizophrenia 4:1.
Crossref
Dominik Strzelecki, Małgorzata Urban-Kowalczyk & Adam Wysokiński. (2018) Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Research 268, pages 447-453.
Crossref
Chieh-Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, Yu-Jhen Huang, Po-Wei Chen, Hui-Ting Yang & Hsien-Yuan Lane. (2018) Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry 84:6, pages 422-432.
Crossref
Joshua T. Kantrowitz, Neal R. Swerdlow, Walter Dunn & Sophia Vinogradov. (2018) Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate–Type Glutamate Receptor Function. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 3:7, pages 581-590.
Crossref
Peter Piper. (2018) Potential Safety Issues Surrounding the Use of Benzoate Preservatives. Beverages 4:2, pages 33.
Crossref
Gerson D. Guercio & Rogerio Panizzutti. (2018) Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer. Frontiers in Psychiatry 9.
Crossref
Joshua T. Kantrowitz. (2017) Managing Negative Symptoms of Schizophrenia: How Far Have We Come?. CNS Drugs 31:5, pages 373-388.
Crossref
Henry Sershen, Audrey Hashim, David S. Dunlop, Raymond F. Suckow, Tom B. Cooper & Daniel C. Javitt. (2016) Modulating NMDA Receptor Function with d-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model. Neurochemical Research 41:1-2, pages 398-408.
Crossref
G.E. Tsai. 2016. Neuropsychopharmacology: A Tribute to Joseph T. Coyle. Neuropsychopharmacology: A Tribute to Joseph T. Coyle 257 309 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.